Recent Company News

• 07:02 AM ET Dec 11, 2025
  

  Molecular Partners forms scientific advisory board to accelerate development of targeted radiotherapeutics (CHF 3.45, +0.11)

• 10:32 AM ET Dec 07, 2025
  

  Molecular Partners to present updated data from Phase 1/2a trial of MP0533 at ASH Annual Meeting (CHF 3.39, 0.00)

• 04:26 AM ET Nov 03, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:12 AM ET Nov 12, 2025
  

  Molecular Partners presents new data for DLL3 targeting radiotherapy MP0712 at TRP Summit Europe 2025 (CHF 3.10, 0.00)

• 09:20 AM ET Nov 03, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:27 AM ET Nov 03, 2025
  

  StreetAccount Summary - US Pre-market trading

• 01:05 AM ET Nov 03, 2025
  

  Molecular Partners to present updated data from Phase 1/2a trial of MP0533 in AML at ASH Annual Meeting (CHF 2.90, 0.00)

• 04:07 PM ET Oct 30, 2025
  

  Molecular Partners reports financial results and clinical progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025 (CHF 3.03, 0.00)